Pathogenic role of interleukin-6 in the development of sepsis.: Part II:: Significance of anti-interleukin-6 and anti-soluble interleukin-6 receptor-α antibodies in a standardized murine contact burn model

被引:31
|
作者
Pallua, N [1 ]
Low, JFA [1 ]
von Heimburg, D [1 ]
机构
[1] Rhein Westfal TH Aachen, Univ Hosp, Dept Plast Surg & Hand Surg, Burn Ctr, D-52057 Aachen, Germany
关键词
interleukin-6; cytokines; cytokine antagonism; burn; sepsis; systemic inflammation; endotoxin;
D O I
10.1097/01.CCM.0000065725.80882.BD
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objective: The in vivo effects of anti-interleukin-6 (anti-IL-6) and anti-interleukin-6-alpha receptor (anti-IL-6R) monoclonal antibodies on immune response and survival rate of a burn with subsequent infection were assessed. Subjects: Ten-week-old C 57 BL/6J mice received a standardized contact burn; 48 hrs later endotoxin (LPS) was injected intraperitoneally to induce systemic inflammation. Ten different groups were studied. Groups I-IV sustained a burn and/or a LPS-stimulus but did not receive any anti-cytokines and served as controls. Treatment groups V-X sustained the same injuries but also received anti-IL-6 and anti-IL-6R intravenously either before or after the LPS stimulus. In a further part of the study, a lethal dose of LPS was injected (LPS-LD100 group) followed by an injection of anti-IL-6 antibody and/or anti-IL-6R antibody. Measurements: Serum concentrations of IL-6, tumor necrosis factor (TNF)-alpha, interferon (IFN)-gamma, and white blood cell and platelet counts were determined, and the survival rate over a 2-wk period was assessed. Results: Treatment with anti-IL-6 slightly decreased the inflammatory response when it was given before or after LIPS application. The inflammatory response was not decreased after treatment with anti-IL-6R. In the groups that received a combination of anti-IL-6 and anti-IL-6R, there was a significant reduction of the inflammatory response. This was more pronounced when the anti-cytokines were applied after LPS application. A significant reduction in mortality could be shown with both antibodies in the treatment groups and the groups that had received a lethal dose of LPS (LPS-LD100 group). Conclusions: IL-6 has a low inflammatory potential, and IL-6R has no inflammatory potential by itself. In contrast, the IL-6/IL-6R complexes have a higher inflammatory potential. Mortality could be reduced by each antibody alone as well as by the combination, supporting the hypothesis that the inflammatory and lethal potentials of IL-6 are not identical. The study suggests that the use of antibodies against IL-6 or IL-6R is effective in the prevention of systemic inflammation in a murine burn model.
引用
收藏
页码:1495 / 1501
页数:7
相关论文
共 46 条
  • [1] Pathogenic role of interleukin-6 in the development of sepsis. Part I: Study in a standardized contact burn murine model
    Pallua, N
    von Heimburg, D
    CRITICAL CARE MEDICINE, 2003, 31 (05) : 1490 - 1494
  • [2] Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease
    Ridker, Paul M.
    Rane, Manas
    CIRCULATION RESEARCH, 2021, 128 (11) : 1728 - 1746
  • [3] The clinical role of interleukin-6 and interleukin-6 soluble receptor in human follicular fluids
    Kawasaki, F
    Kawano, Y
    Hasan, ZK
    Narahara, H
    Miyakawa, I
    CLINICAL AND EXPERIMENTAL MEDICINE, 2003, 3 (01) : 27 - 31
  • [4] The role of interleukin-6 as an early predictor of sepsis in a murine sepsis model
    Badea, Iudita Maria
    Azamfirei, Razvan
    Grigorescu, Bianca Liana
    Raduly, Gergo
    Hutanu, Adina
    Petrisor, Marius
    Lazar, Alexandra Elena
    Almasy, Emoke
    Fodor, Raluca Stefania
    Man, Adrian
    Szederjesi, Janos
    Gurzu, Simona
    Azamfirei, Leonard
    Georgescu, Anca Meda
    ROMANIAN JOURNAL OF MORPHOLOGY AND EMBRYOLOGY, 2019, 60 (01) : 69 - 75
  • [5] Analysis of the mechanism of action of anti-human interleukin-6 and anti-human interleukin-6 receptor-neutralising monoclonal antibodies
    Kalai, M
    MonteroJulian, FA
    Brakenhoff, JPJ
    Fontaine, V
    DeWit, L
    Wollmer, A
    Brailly, H
    Content, J
    Grotzinger, J
    EUROPEAN JOURNAL OF BIOCHEMISTRY, 1997, 249 (03): : 690 - 700
  • [6] Regulation of growth of prostate cancer cells selected in the presence of interleukin-6 by the anti-interleukin-6 antibody CNTO 328
    Steiner, Hannes
    Cavarretta, Ilaria T.
    Moser, Patrizia L.
    Berger, Andreas P.
    Bektic, Jasmin
    Dietrich, Hermann
    Zaki, Mohamed H.
    Nakada, Marian
    Hobisch, Alfred
    Nemeth, Jeffrey A.
    Culig, Zoran
    PROSTATE, 2006, 66 (16) : 1744 - 1752
  • [7] Role of the interleukin-6/interleukin-6 soluble receptor cytokine system in mediating increased skeletal sensitivity to parathyroid hormone in perimenopausal women
    Insogna, K
    Mitnick, M
    Pascarella, J
    Nakchbandi, I
    Grey, A
    Masiukiewicz, U
    JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 : N108 - N116
  • [8] Imaging of lesions in a murine rheumatoid arthritis model with a humanized anti-interleukin-6 receptor antibody
    Sugimoto, K
    Nishimoto, N
    Kishimoto, T
    Yoshizaki, K
    Nishimura, T
    ANNALS OF NUCLEAR MEDICINE, 2005, 19 (04) : 261 - 266
  • [9] Imaging of lesions in a murine rheumatoid arthritis model with a humanized anti-interleukin-6 receptor antibody
    Kanji Sugimoto
    Norihiro Nishimoto
    Tadamitsu Kishimoto
    Kazuyuki Yoshizaki
    Tsunehiko Nishimura
    Annals of Nuclear Medicine, 2005, 19 : 261 - 266
  • [10] The Role of the Soluble Interleukin-6 Receptor in the Progression of Nonalcoholic Fatty Liver Disease
    I. V. Kurbatova
    L. V. Topchieva
    O. P. Dudanova
    A. A. Shipovskaya
    Bulletin of Experimental Biology and Medicine, 2023, 174 : 628 - 633